Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Roche announces outcomes for Avastin-Tarceva

Roche announces outcomes for Avastin-Tarceva

9th October 2008

Roche has announced topline outcomes in its combination study of Avastin (bevacizumab) and Tarceva (erlotinib) in patients with advanced lung cancer.

It said this phase III data showed evidence of potential benefits to individuals with this condition.

The results of the BeTa Lung study compared the use of Avastin-Tarceva with Tarceva alone in the second-line treatment of advanced non-small cell lung cancer.

Roche said the trial did not meet its primary endpoint of a significant increase in overall survival of the combination therapy, while further analyses are being conducted, including post-progression therapy.

The trial did show improvements in secondary endpoints of progression-free survival and response rates.

William M Burns, chief executive officer of the pharmaceuticals division of Roche, said: “Advanced lung cancer has a very poor prognosis and is an extremely difficult-to-treat disease.

“We are encouraged to see that the combination of Avastin and Tarceva showed evidence of clinical activity for the patients.”

He added the study results do not affect the existing approved indications for either compound, while the company remains dedicated to the development of new treatments for on-small cell lung cancer.

Earlier this week, Roche announced a partnership with Genentech and GlycArt to develop and market a new potential cancer treatment.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.